M7824 is a bifunctional fusion protein which targets transforming growth factor-beta (TGF-beta) and programmed death-ligand 1 (PD-L1). This makes it suited to HPV-positive squamous cell carcinoma of the head and neck, as the TGS signalling pathway in this indication is frequently dysregulated. At...
In this interview at ESMO 2018, Dr Yungan Tao speaks about the GORTEC 2004-01 randomised phase III trial which looked at 70 Gy/35 F with conventional radiotherapy versus 75 Gy/35 F with intensity-modulated radiotherapy. Dr Tao explains the results and limitations of the study and how this...
Dr Ulrich Keilholz discusses first- and second-line treatments for recurrent/metastatic squamous cell carcinoma of the head and neck.
FILMED AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING, OCTOBER 2016.
Dr Sudhir V Nair - (Tata Memorial Centre, Mumbai, India) talks to ecancertv at IAOO 2015 about the positioning of chemotherapy in the strategy against locally advanced oral cavity cancer.
Dr Tanguy Seiwert (University of Chicago, Chicago, USA) talks to ecancertv at ASCO 2015 about a 132-patient study indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC).
Mayo Clinic surgeon Geoffrey Young, M.D., Ph.D.. He is a head and neck surgeon at Mayo Clinic in Florida. In this video he the use of Transoral Robotic Surgery (TORS) to treat certain tumors of the head and neck.